收入稳健增长，推进新药研发持续赋能

| --- | --- | --- | --- | --- | --- | --- | |-------|----------------------------------------------------|-----------------|---------------|-----------------|-----------------|-----------------| | | [T主ab 要le财 _P务ro指fit]标 \n营业总收入 (百万元) | 2022A \n 2,331 | 2023A \n2,866 | 2024E \n 3,565 | 2025E \n 4,339 | 2026E \n 5,108 | | | 增长率 YoY % | 7.5% | 22.9% | 24.4% | 21.7% | 17.7% | | | 归属母公司净利润(百 万元 ) | 703 | 847 | 1,016 | 1,231 | 1,448 | | | 增长率 YoY% | 240.3% | 20.5% | 19.9% | 21.2% | 17.6% | | | 毛利率 % | 78.4% | 7 ...